Answers are grounded in this paper and cite their sources.
TRIAC therapy in RTHβ relieves hyperthyroid symptoms and lowers resting energy expenditure and circulating thyroid hormones without worsening hepatic hormone resistance or exacerbating cardiac thyromimetic activity. Future clinical trials to determine whether TRIAC treatment alters adverse cardiovascular outcomes in this disorder are warranted.
No takes yet. Share an insight, caveat, or question.
Moran et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: